Sessions

 

Session 5

 

Tuesday, September 1
8:00 – 10:00 am

Room: Poulenc     

Management of locally advanced esophageal cancer

Contemporary options and controversies

 

     
Chairs: David H. Ilson (USA) – Tie-Hua Rong (China)

Discussant: Paul M. Schneider (Switzerland)

 

Preoperative chemotherapy versus chemoradiotherapy in esophageal and GE junction adenocarcinoma: what is the status of the current debate?

• Case presentation before and after debate:  a 58 year old male with a T3N1 GE junction adenocarcinoma.
• Preoperative Chemotherapy.
• Preoperative Chemoradiotherapy. David H. Ilson (USA)
  
  

What is optimal therapy for squamous cancer of the esophagus: chemotherapy, chemoradiotherapy, or surgery?

• Case presentation before and after debate: a 63 year old woman with a distal third squamous cancer of the esophagus, T3N1.
• Chemoradiotherapy without surgery. Mark Krasna (USA) 
• Surgery is mandatory regardless of preoperative therapy. Richard van Hillegersberg (Netherlands)
  
  

HER2 and other Biomarkers: What is the status of targeted therapies in combined modality therapy of esophageal cancer?

• Didactic Lecture: What is the status of targeted therapies in combined modality therapy of esophageal cancer? David H. Ilson (USA)
• Case presentation before and after lecture: a 60 year old man presents with a T3N1 GE junction adenocarcinoma, 3+ for HER2.
  
  

Panel discussion